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. In more than 85 % of cases, the duration of CJD is less than one year (median: four months) after the onset of symptoms.
Types of CJD include Sporadic (sCJD) caused by a mutation arising in an individual of unknown reason and this accounts for 85% cases of CJD 2 . Varient (vCJD) caused by consuming food contaminated with prion. Familial ( f CJD) caused by an inherited mutation & accounts for the other 15 % cases of CJD. Iatrogenic caused by contamination of tissue from infected person usually as a result of medical procedure e.g. corneal & meningeal transplant, blood transfusion. Diagnosis solely based on typical clinical manifestation, characteristic EEG findings, presence of 14-3-3 protein in CSF assay 3 , MRI of brain -high signal intensity in caudate nucleus & putamen symmetrically on T2WI and DWI are most sensitive 4 . The present manuscript reports encounter in NUH, Singapore and UHL, Dhaka known as sporadic CJD (sCJD).
Case Report:
A 67 years old highly educated active lady admitted at 1. Dr. Noor-E-Jabeen. MBBS. Senior House officer. Figure 2 ),. She had been thoroughly evaluated in NUH Singapore and concluded the diagnosis of sCJD.
Discussion:
sCJD is a human prion disease rapidly progressive, invariably fatal, neurodegenerative disease that occurs worldwide. The majority of CJD patients usually die within one year of onset of illness. CJD is classified as a transmissible spongiform encephalopathy along with other prion disease that occur in human & animals 5 .
Patient initially became symptomatic with rapidly progressive dementia leading to memory loss, personality change,
Case Report
An elderly lady with dementia and myoclonus : Think of Sporadic Creutzfeldt Jakob Disease There is no cure of CJD. No drug yet is available to stop the progression of disease. However some medications are in clinical trial. Pentosan polysulphate may slow the progression of disease. Amphotericin-B & doxorubicin as yet there is no strong evidence that either drug is effective in stopping the disease. Quinacrine permanently cleared abnormal prion protein from cell culture but had no measurable effect on clinical course of CJD 8 . Aztemizole have anti-prion activity may be effective for the treatment of CJD. Current treatment aims are to alleviate symptoms and make the patient as comfortable as possible.
Conclusion:
sCJD though it is rare but may be missed due to lack of suspicion & diagnostic facilities. Any rapidly progressing demantic patient with myoclonus should have to be evaluated with CSF assay, EEG & MRI of brain, though no specific treatment are yet available till the disease CJD remains incurable . However extensive research is going on to find out an effective & curable drugs for CJD in future.
